The therapeutic potential of 5-HT2C signaling pathway was highlighted by the clinical use of lorcaserin, a selective 5-HT2C agonist approved by the Federal Drug Administration (FDA) in 2012 for the treatment of obesity. The gene discussed is HTR2C; the disease is obesity disorder.